HomeCompareCYT vs PLD

CYT vs PLD: Dividend Comparison 2026

CYT yields 66.23% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.03M in total portfolio value· pulled ahead in Year 9
10 years
CYT
CYT
● Live price
66.23%
Share price
$3.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$880.0K
Annual income
$221,634.45
Full CYT calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CYT vs PLD

📍 PLD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYT + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYT pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYT
Annual income on $10K today (after 15% tax)
$5,629.14/yr
After 10yr DRIP, annual income (after tax)
$188,389.28/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,849,727.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYT + PLD for your $10,000?

CYT: 50%PLD: 50%
100% PLD50/50100% CYT
Portfolio after 10yr
$3.39M
Annual income
$2,486,179.81/yr
Blended yield
73.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CYT
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Price Target
$2.00
-33.8% upside vs current
Range: $2.00 — $2.00
Altman Z
9.4
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYT buys
0
PLD buys
0
No recent congressional trades found for CYT or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTPLD
Forward yield66.23%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$880.0K$5.91M
Annual income after 10y$221,634.45$4,750,725.19
Total dividends collected$742.8K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$2.00$136.00

Year-by-year: CYT vs PLD ($10,000, DRIP)

YearCYT PortfolioCYT Income/yrPLD PortfolioPLD Income/yrGap
1$17,323$6,622.52$11,241$540.96+$6.1KCYT
2$29,256$10,721.37$13,019$991.13+$16.2KCYT
3$48,227$16,923.00$15,801$1,870.97+$32.4KCYT
4$77,675$26,071.48$20,609$3,701.21+$57.1KCYT
5$122,356$39,243.54$29,919$7,867.97+$92.4KCYT
6$188,694$57,773.40$50,631$18,617.74+$138.1KCYT
7$285,170$83,268.01$105,528$51,352.20+$179.6KCYT
8$422,742$117,609.16$287,364$174,449.42+$135.4KCYT
9← crossover$615,273$162,940.02$1,081,760$774,280.77$466.5KPLD
10$879,977$221,634.45$5,908,209$4,750,725.19$5.03MPLD

CYT vs PLD: Complete Analysis 2026

CYTStock

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Full CYT Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CYT vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYT vs SCHDCYT vs JEPICYT vs OCYT vs KOCYT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.